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OBJECTIVES: To describe the referrals and their flow within and outside  
the referral networks, and examine the effects of the audit on the adherence  
to referral guidelines and quality of services. METHODS: First, series of meetings 
were held with study teams (5 referral networks, district and regional 
management officers) to provide a framework for the referral cycle.  
The framework then provided the basis for the implementation of 2 referral 
audit cycles of 3 months each by each referral network. The audit cycle involved 
data collection, analysis, action plan formulation, action plan implementation, 
and reassessing the situation with another cycle. A total of 12 health centers  
and 4 hospitals participated in the study. The first 4 referral networks had a 
midwife and the head midwife from the health centres district hospital 
respectively as member. The lead midwifes from the district and regional 
hospitals constituted the fifth network. RESULTS: Over 90% of the 446 referrals 
were mothers with maternal related complications. Cycle 2 findings shows 
improvement in quality of care provided for patients. For instance, an increase 
in; partograph use from 40% to 50%, feedback to home facility from 37% to  
58%, health worker accompanying referred patient from 64% to 80%, health 
workers calling ahead of referrals from 38% to 65%, and absence of key staff 
decreased about 20% to 2%. Poor adherence to referral procedures, lack of 
networking among providers, absence of key staff, Socio-cultural beliefs, poor 
transportation were the main barriers to quality of care. CONCLUSIONS: 
Establishment of formal and informal networks among providers, community 
level engagement, and availability of referral protocol and adherence facilitate 
good quality of care.  
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OBJECTIVES: To examine the effects of U.S. federal parity legislation on 
substance use disorder treatment in the first year after passage. METHODS: We 
used insurance claims data from Aetna Inc. health plans in ten states with state-
level parity laws for substance use disorder treatment. We used a difference-in-
differences study design to compare changes in outcomes among self-insured 
health plan enrollees subject to federal parity in the years before and after 
implementation of federal parity (2009-2010) with changes in outcomes among a 
comparison group of fully insured health plan enrollees previously covered by 
state substance use disorder parity laws (N=298,339). Outcomes included: shares 
of enrollees using any substance use disorder treatment; annual total spending 
on substance use disorder treatment; out-of-pocket spending on substance use 
disorder treatment and three substance use disorder performance measures: 
identification, treatment initiation and treatment engagement. RESULTS: In the 
first year of implementation, federal parity did not lead to changes in the 
proportion of enrollees using substance use disorder treatment. Total spending 
on substance use disorder treatment per enrollee increased more for self-insured 
enrollees subject to federal parity than for fully-insured enrollees ($16.11 vs. 
$6.12, difference $9.99, 95% CI: $2.54 to $18.21). Federal parity was not associated 
with any statistically significant changes in identification, treatment initiation or 
treatment engagement. CONCLUSIONS: Inclusion of substance use disorder 
services in the federal parity law did not result in substantial increases in health 
plan spending. It will be critical to evaluate the effects of federal parity in more 
recent data, after regulations affecting the management of care (e.g., utilization 
review, network access) took effect.  
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ABDOMINAL AORTIC ANEURYSM SCREENING: THE IMPACT OF THE SAAAVE 
ACT OF 2007  
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Tufts Medical Center, Boston, MA, USA  
OBJECTIVES: Abdominal aortic aneurysm (AAA) is typically asymptomatic,  
but over time may lead to a rupture of the aorta, with a high fatality rate. The 
Screening AAA Very Efficiently (SAAAVE) Act of 2007 adds a new preventative 
service as part of the Welcome to Medicare visit (WTM), a free one-time AAA 
screening for men with smoking history, and men and women with a family 
history of AAA. This study aimed to estimate utilization of the new benefit  
and its impact on AAA diagnostics and treatment. METHODS: We analyzed 
Medicare claims data (2005-2009) to estimate Welcome to Medicare examination 
utilization (CPT codes G0344 and G0402) among new enrollees, and use of  
the new AAA screening benefit (CPT code G0389). We also examined utilization 
of AAA-related diagnostics and treatment from 2005 to 2009, i.e., two years  
prior to and following the 2007 adoption of the new benefit. RESULTS: Medicare 
data revealed very low uptake of AAA screening among newly enrolled Medicare 
beneficiaries, with rates of less than 1% each year, and under 1% among  
those eligible for the screening benefit. The number of newly enrolled 
beneficiaries newly diagnosed with AAA ranged from 6,660 to 9,260 per year, 
increasing over time. AAA-related use of abdominal ultrasound has decreased 
from 13 per 100 AAA patients in 2005 to 10 per 100 AAA patients in 2009.  
Overall AAA repair procedure rates have remained constant at 7 per 100  
AAA patients, with endovascular repair use increasing and open repair use 
decreasing. CONCLUSIONS: Medicare data showed that the Welcome to 
Medicare (WTM) visit for new enrollees and the AAA screening  
benefit established by the 2007 SAAAVE Act have been underutilized, and have 
not affected diagnostic and repair procedure rates for AAA. The need for 
screening remains, given that AAA incidence is not declining in Medicare 
beneficiaries.  
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OBJECTIVES: Proton pump inhibitors (PPIs) are commonly used in children for 
treating gastroesophageal reflux disease and erosive esophagitis symptoms. 
However, the safety profile for long-term use of PPIs in children is still largely 
unclear. The objective of this study was to identify the adverse events (AEs) 
associated with pediatric PPI use and stratify them by individual PPI, age of 
patient (child versus infant), and whether the PPI was a primary suspect drug or 
used with other medications. PPI use has been related to respiratory infections 
as well as activity-related bone fractures. Children with asthma are much more 
likely to be treated with a PPI than nonasthmatic children. METHODS: A 
retrospective, descriptive analysis was conducted. Reports of AEs related to PPIs 
from 1997 through 2011 for children (aged 1-17 years) and infants (<1 year old) 
were retrieved from the FDA Adverse Event Reporting System. RESULTS: A total 
of 112,060 reports were retrieved for children. Of these, 53.8% were for 
omeprazole, 24.7% for lansoprazole, 9.9% for esomeprazole, 10.1% for 
pantoprazole, and 1.5% for rabeprazole and dexlansoprazole combined. There 
were 14,122 deaths, 9,221 associated with omeprazole. There were 46,046 initial 
or prolonged hospitalizations. There were 6093 reports of disability. The majority 
(92,954) of the reports involved concomitant use of a PPI; the PPI was the primary 
or secondary suspect drug in the remainder of the reports. There were 3,794 
reports retrieved for infants, of which 38.9% were associated with omeprazole 
and 39.8% with lansoprazole. There were 500 reports of infant deaths, with 236 
associated with omeprazole. There were 1,524 events involving hospitalization. 
Concomitant use of PPIs accounted for 3198 (84.3%) of the reports. 
CONCLUSIONS: Pediatric PPI-related AEs involved death, hospitalization, 
disability, and life-threatening outcomes. Further investigation is warranted. 
Currently, the FDA recommends that health care providers deliver the shortest, 
lowest-dose PPI regimen as possible.  
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PATIENT CHARACTERISTICS AND DRUG UTILIZATION AMONG HEPATITIS C 
(HCV) PATIENTS IN A LARGE PAYER DATABASE  
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OBJECTIVES: To investigate the characteristics of Chronic Hepatitis C (CHC) 
patients, their co-morbid conditions, treatments and associated costs using large 
health care payer databases. METHODS: This retrospective study used data from 
Truven Health Analytics MarketScan databases from January 1, 2006-March 31, 
2012. Adult patients with ≥2 diagnosis claims of chronic HCV (CHC) were 
selected. They had at least six months of continuous health plan and drug plan 
enrollment pre/post index date. CHC patients were grouped by disease severity 
as non-cirrhotic disease (NCD), compensated cirrhosis (CC), or end-stage liver 
disease (ESLD). Co-morbidities, treatment rates, health care utilization, and cost 
were assessed by disease severity. RESULTS: 57,084 CHC patients met inclusion 
criteria, of whom 43,561 (76.3%) were NCD, 6,830 (12.0%) were CC, and 6,693 
(11.7%) were ESLD. Mean age was 50.6 yrs [standard deviation (SD) =10.1]. 58.1% 
of patients were male and 73.8% had commercial insurance. Common co-
morbidities included type II diabetes (DM) (13.3%), substance abuse (14.5%), and 
depression (11.7%). Diagnosis of DM and substance abuse increased with disease 
severity (DM diagnosed in 14%/20%/27% and substance abuse in 20%/22%/26% of 
NCD/CC/ESLD CHC patients, respectively). Detection of all three co-morbidities 
increased following HCV diagnosis. Depression increased from 12% to 16% 
following HCV diagnosis. Anemia was highly prevalent following diagnosis 
(12.3%), especially in the ESLD cohort (28.3%). In the six months following HCV 
diagnosis, utilization of inpatient, hospital outpatient, emergency room, 
physician office, and pharmacy services increased significantly. During the study 
period, 10.9% of the population received treatment for HCV, 83.1% with dual 
therapy compared to 13.2% with telaprevir and 3.4% with boceprevir-based triple 
therapy. The modest use of the protease inhibitors likely reflects their coming to 
market in 2011. CONCLUSIONS: A small percentage of CHC patients receive 
treatment. DM, substance abuse, and depression are common among patients 
chronically infected with HCV. Health care utilization increased after CHC 
diagnosis.  
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OBJECTIVES: Baseline viral load (BVL) is a known predictor of time to treatment 
response (achievement of undetectable viral load, UVL) in CHB studies. No 
A212 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
published NMAs have accounted for this variable when assessing the relative 
efficacy of CHB interventions. We undertook baseline-adjusted and -unadjusted 
analyses using the same dataset to explore the impact of BVL on UVL 
achievement. METHODS: The NMA was undertaken in WinBUGs using standard 
fixed/random effects approaches. A systematic literature review was the source 
of efficacy data for eight interventions. Individual patient data from an entecavir 
RCT was used to quantify the impact of different baseline characteristics on the 
likelihood of achieving UVL at one year. Study level mean baseline values from 
all identified papers and the results from the abovementioned analysis were 
used to inform prior distributions in the adjusted analysis. Results were 
presented as relative risks (RRs) at one year and 95% credible intervals. Entecavir 
was the reference treatment. Sensitivity analyses surrounding the 
inclusion/exclusion of individual studies were performed. RESULTS: Entecavir 
and tenofovir studies included heterogeneous patient populations in terms of 
BVL (mean entecavir value 9.29 log10copies/ml, tenofovir value 8.65 
log10copies/ml). After adjusting the UVL for baseline viral load using an 
informative prior, the RR for entecavir versus tenofovir went from statistically 
significant to non-significant [unadjusted: RR 1.43 (1.30 to 1.54), adjusted: RR 1.21 
(0.48 to 1.51)]. Relative efficacy results for all other interventions were similar 
across adjusted and unadjusted analyses. Adjusted results were robust to the 
inclusion/exclusion of additional studies. Adjusted results for all interventions 
were consistent with clinical trial data. CONCLUSIONS: Adjusted and unadjusted 
NMA, using the same dataset, demonstrated the importance of adjusting for BVL 
when assessing the relative efficacy of CHB interventions. Failing to account for 
differences in BVL across studies may result in flawed relative efficacy estimates.  
 
PGI4  
CONSIDERATIONS OF PRACTICAL CHALLENGES IN CONDUCTING MIXED 
TREATMENT COMPARISONS OF PHARMACOTHERAPIES FOR CHRONIC 
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Jalundhwala YJ, Lin FJ, Patel H 
University of Illinois at Chicago, Chicago, IL, USA  
OBJECTIVES: In absence of head-to-head trials and over hundred new molecules 
in clinical development for hepatitis C virus (HCV) infection, mixed treatment 
comparisons continue to play a crucial role in guiding clinical decision making. 
This study was aimed to identify the practical challenges of conducting mixed 
treatment comparisons in chronic HCV genotype-1 patients, especially in 
subgroups with clinical factors that are associated with poor treatment response 
and/or increased risks. METHODS: A systematic review was conducted to 
identify randomized controlled trials of telaprevir (TVR) and boceprevir (BOC) in 
HCV genotype-1 patient population. Included clinical trials were assessed to 
check: 1) if clinical factors related to poor treatment response (race, prior viral 
load, grade of underlying cirrhosis/fibrosis) were reported and subgroup analyses 
were conducted; and 2) if important safety endpoints (rash, anemia, 
neutropenia) were reported with a clear definition of the gradient of severity. 
RESULTS: A total of eight trials were identified: five in treatment-naïve patients 
(4TVR, 1BOC) and three in treatment-experienced patients (2TVR, 1BOC). Among 
the seven trials which reported the proportion of African Americans and 
information on grade of fibrosis, two did not conduct subgroup analyses 
accordingly. Of the trials reporting prior viral load (8) and cirrhosis (5), only three 
and two trials presented related subgroup analyses, respectively. Severity of 
important safety endpoints such as rash and anemia was not defined in four of 
the studies (50%), mainly telaprevir trials, and neutropenia was not defined in 
almost two-thirds (5/8). CONCLUSIONS: From an already small pool of studies to 
begin with, unavailability of data and lack of safety endpoint definitions are 
challenges that may reduce the feasibility and increase potential biases for 
conducting mixed treatment comparisons. Overcoming these identified 
challenges will improve understanding of the comparative efficacy and safety of 
HCV drugs, particularly in the at-risk population.  
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GEOGRAPHIC VARIATION TRENDS OF CROHN'S DISEASE PREVALENCE AND 
DEMOGRAPHIC CHARACTERISTICS IN THE UNITED STATES VETERAN 
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OBJECTIVES: This study aimed to assess the association of Crohn’s disease 
prevalence with demographic characteristics in the U.S. veteran population. 
METHODS: This study analyzed a patient sample from the Veterans Health 
Administration (VHA) Medical SAS datasets from October 1, 2005 to May 31, 2012. 
All patients diagnosed with Crohn’s disease during 2011 were identified using 
International Classification of Disease 9th Revision Clinical Modification (ICD-9-
CM) diagnosis code 555. Patients with medical benefits enrollment not covering 
2011 were excluded. Study patient demographic information was then captured 
and categorized into groups. All descriptive statistical analyses were performed 
using SAS v9.3 software. RESULTS: For VHA patients diagnosed in 2011 with 
Crohn’s disease (N=41,418), prevalence varied by race as follows: Non-Hispanic 
White (0.23%), Non-Hispanic Black (0.14%), Hispanic (0.09%) and other races 
(0.13%). When stratified by age, the highest prevalence was observed in the 
higher age groups: 55-64 (0.21%), 35-54 (0.20%), and 65+ (0.17%). Based on the 
examination of Crohn’s disease prevalence in different states, the disease was 
found to be most likely diagnosed in Maine (0.35%), Vermont (0.29%), Connecticut 
(0.28%) and New Hampshire (0.24%). On the contrary, Puerto Rico (0.07%), 
Washington D.C. (0.07%) and Hawaii (0.06%) showed the lowest prevalence. 
However, the difference was never greater than 0.3%. CONCLUSIONS: The 
uneven distribution of Crohn’s disease among U.S. states suggests a geographic 
variation in risk areas that may be useful for future targeted intervention 
strategies. Further research may be necessary for middle-aged and elderly 
patient groups to prevent this disease.  
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OBJECTIVES: To estimate pharmacy and overall budgetary impact of introducing 
linaclotide to a hypothetical one-million-member managed care plan. 
METHODS: A decision-tree model (one-year time horizon) was constructed to 
estimate the budgetary impact of linaclotide. Model inputs include plan 
population, treatment costs, estimated current and future monthly prescription 
utilization, response rates, and potential medical cost offsets. Model outputs are 
per-member per-month (PMPM) pharmacy and medical costs. Treatment options 
include linaclotide, lubiprostone, and other prescription therapies. The 
proportion of patients who respond to linaclotide are assumed to incur lower 
health care costs due to less health care utilization. Treatment costs are based 
on published prices (polyethylene glycol, the most common prescription therapy 
is used as a surrogate for other generically-available prescription therapies). 
Daily net treatment costs (payer perspective) are $5.50, $6.37, and $0.29 for 
linaclotide, lubiprostone, and polyethylene glycol, respectively. Current 
prescription utilization (14% lubiprostone, 86% other therapies) and potential 
annual per-patient medical cost offsets (IBS-C: $1781, CC: $2002) are derived from 
retrospective database analyses; future prescription utilization (8% linaclotide, 
10% lubiprostone, 82% other) is assumed. Linaclotide response rates (IBS-C: 
33.6%, CC: 18.6%) are from primary endpoints of Phase III clinical trials. 
Budgetary impact is calculated as the cost difference between current and future 
scenarios. One-way sensitivity analyses were performed. RESULTS: Introducing 
linaclotide to a managed care formulary is estimated to increase the pharmacy 
budget by $0.007 PMPM; when potential medical cost offsets are included, the 
resulting overall budgetary impact is estimated to be $0.003 PMPM. In sensitivity 
analyses, number of linaclotide patients, IBS-C cost offsets, and conversion from 
other therapies to linaclotide had the greatest influence on budgetary impact; 
however, results did not vary substantially from base-case. CONCLUSIONS: 
Linaclotide is expected to result in a slight increase in pharmacy budgets which 
may be partially offset by medical cost savings.  
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PROJECTED ECONOMIC IMPACT OF CURRENT AND FUTURE CHRONIC 
HEPATITIS C TREATMENT REGIMENS AND RECENT SCREENING GUIDELINES IN 
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Clark RS, Campell CM, O'Day K, Denno MS, Dandappanavar AS, Regan TS, Jackson JH, 
Meyer K 
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OBJECTIVES: Hepatitis C virus (HCV) infection is a chronic disease affecting the 
liver that may lead to cirrhosis and result in costly outcomes including ascites, 
variceal bleeds, encephalopathy, hepatocellular carcinoma (HCC), and liver 
transplant. The purpose of this study is to evaluate the overall cost burden of 
genotype 1 chronic HCV patients treated with current triple therapy regimens 
(protease inhibitor/peginterferon alfa/ribavirin) or future quadruple therapy 
regimens (polymerase or NS5A inhibitor/protease inhibitor/peginterferon 
alfa/ribavirin), and the incremental cost burden of patients identified as having 
chronic HCV by new screening guidelines. METHODS: A 50-year Markov cohort 
model was developed to compare current and future HCV treatment regimens. 
Patients who achieved sustained virologic response (SVR) were considered 
responders and were assigned a decreased level of progression to HCC, liver 
transplant, and liver-related mortality. Cost inputs, including pharmacy and 
medical costs associated with progressive HCV-related liver disease, were 
derived from published sources and Redbook. Treatment effectiveness, 
adherence rates, and transition probabilities for responders and non-responders 
were derived from published sources. SVR for quadruple therapy was derived 
from interim phase II trial results. Cost and outcomes were discounted at 3% and 
tested with a one-way sensitivity analysis. RESULTS: The discounted cost to 
treat a patient with triple therapy is US$150,790, including pharmacy costs and 
hepatic sequelae. Assuming treatment at time of drug approval, the 
corresponding discounted cost for quadruple therapy is projected at US$205,045 
per patient. Based on proposed screening guidelines, approximately 150,000 
additional chronic HCV patients will be both diagnosed and treated. The 
incremental discounted cost of treating these additional patients with quadruple 
therapy is projected to be $28.5 billion and is due in part to increased patient 
lifespan. CONCLUSIONS: New screening guidelines and therapeutic advances are 
projected to improve patient utilization of more effective treatments and result 
in an increased level of health care spending.  
 
PGI8  
COMORBIDITIES, MEDICATIONS, HEALTH CARE COSTS AND UTILIZATIONS OF 
VETERAN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE IN THE 
UNITED STATES  
Xie L1, Du J1, Baser O2 
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research/The University of Michigan, 
Ann Arbor, MI, USA  
